Sai Parenteral's came to market through an IPO that opened on 24 March 2026 and closed on 27 March 2026, and the shares listed on 2 April 2026 on BSE, NSE. The price band was ₹372 to ₹392 per share and one lot was 38 shares, so the minimum application was ₹14,896. The issue size was ₹408.79 crore. It combined a fresh issue of new shares with an offer for sale by existing shareholders.
Bigshare Services Pvt.Ltd was the registrar to the issue, and Arihant Capital Markets Ltd was the lead manager.
As of 27 March 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Established in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research and development and manufacturing. The company has two business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
The company’s product portfolio covers a wide spectrum of pharmaceutical formulations in various therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. The company’s customer base comprises central and state government departments, pharmaceutical companies, public and private sector hospitals, and super stockists across India.
Sai Parenteral’s started its export business in FY 2023 after acquiring two international accredited facilities in Hyderabad, Telangana, and currently serves regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, Middle East, and Africa. The company has five manufacturing facilities in India. Four are located in Hyderabad, Telangana. These are a GMP compliant injectable facility, a WHO-GMP injectable facility, a TGA-Australia and PIC/S accredited solid oral dosage facility, and a WHO-GMP cephalosporin facility.
The company’s wholly owned subsidiary has a GMP certified facility located in Ongole, Andhra Pradesh. As of August 31, 2025, Sai Parenteral's Ltd. had 277 full-time employees.
As described in the offer document.
| Metric | 30-Sep-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Sai Parenterals raises Rs 123 crore via anchor book ahead of IPO. Out of the total allocation, 9.18 lakh shares worth Rs 36 crore were allocated to one domestic mutual fund, namely Quant Mutual Fund, and 7.65 lakh shares worth Rs 30 crore to one insurance company, namely Kotak Mahindra Life Insurance Company.
Kotak Life Sciences Fund also subscribed to 7.65 lakh shares worth nearly Rs 30 crore, followed by Morgan Stanley Asia (Singapore), and India Emerging Giants Fund, which acquired 3.82 lakh shares worth Rs 15 crore and 2.96 lakh shares worth Rs 11.63 crore, respectively.
Anil Kumar Karusala, Vijitha Gorrepati, Karusala Aruna.
Work out the listing gain for this IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Sai Parenteral's IPO was a ₹408.79 crore book-built issue, comprising a fresh issue of ₹285 crore and an offer for sale of ₹123.79 crore. It was priced at ₹372–₹392 per share with a lot size of 38 shares (₹14,896). The IPO was open from March 24 to March 27, 2026 and was subscribed 1.08x. Shares listed on BSE and NSE on April 2, 2026 at ₹400, a 2.0% premium to the issue price of ₹392. Bigshare Services Pvt. Ltd.
is the registrar. Arihant Capital Markets Ltd. is the book running lead manager.
The price band of Sai Parenteral's IPO is ₹372 to ₹392 per share.
The lot size of Sai Parenteral's IPO is 38 shares.
The minimum investment for Sai Parenteral's IPO is approximately ₹14,896 based on the upper price band.
The allotment date of Sai Parenteral's IPO is Mar 30, 2026.
Sai Parenteral's IPO listed on Apr 2, 2026. It was issued at ₹400.0(NSE) and is currently around ₹480.90 as on 2-Nov-2026 3:30 PM, which is approximately 22.7% versus issue price. The 52-week high is ₹706.00.
You can check Sai Parenteral's IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Sai Parenteral's IPO allotment status on Rupix for quick and easy access.
₹372 to ₹392 per share, against a face value of ₹5. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 38 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹14,896.
₹14,896, for one lot of 38 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 24 March 2026 and closed on 27 March 2026.
The basis of allotment was published on 30 March 2026 by Bigshare Services Pvt.Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 2 April 2026 on BSE, NSE.
The issue size was ₹408.79 crore. The fresh issue was 72,70,408 shares (aggregating up to ₹285 crore). The offer for sale was 31,57,880 shares (aggregating up to ₹123.79 crore).